Baseline patient and hospital characteristics, overall and by risk level
| Characteristic . | Overall (N, column %) . | Low risk (column %) . | High risk (column %) . | Unknown risk (column %) . | P . |
|---|---|---|---|---|---|
| Sample N (row %) | 1464 | 706 (48.2%) | 366 (25.0%) | 392 (26.8%) | |
| Age (median, 53 y; IQR, 38-65 y) | .76 | ||||
| ≤39 y | 389 (26.6%) | 26.6% | 24.3% | 28.6% | |
| 40-59 y | 543 (37.1%) | 37.0% | 38.8% | 35.7% | |
| ≥60 y | 532 (36.3%) | 36.4% | 36.9% | 35.7% | |
| Sex | .97 | ||||
| Male | 724 (49.5%) | 49.3% | 49.2% | 50.0% | |
| Female | 740 (50.5%) | 50.7% | 50.8% | 50.0% | |
| Race | .001 | ||||
| White | 1024 (70.0%) | 74.9% | 67.5% | 63.3% | |
| African American | 190 (13.0%) | 11.5% | 13.9% | 14.8% | |
| Other/unknown | 250 (17.1%) | 13.6% | 18.6% | 21.9% | |
| Ethnicity | <.001 | ||||
| Hispanic | 154 (10.5%) | 8.5% | 9.8% | 14.8% | |
| Non-Hispanic | 1124 (76.8%) | 80.7% | 80.1% | 66.6% | |
| Unknown | 186 (12.7%) | 10.8% | 10.1% | 18.6% | |
| Primary payer source | .09 | ||||
| Commercial | 672 (45.9%) | 48.4% | 43.4% | 43.6% | |
| Medicaid | 280 (19.1%) | 17.3% | 22.4% | 19.4% | |
| Medicare | 432 (29.5%) | 30.0% | 26.8% | 31.1% | |
| Other | 80 (5.5%) | 4.3% | 7.4% | 5.9% | |
| AAMC teaching status | .06 | ||||
| Academic medical center | 1353 (92.4%) | 92.4% | 94.8% | 90.3% | |
| Non-academic medical center | 111 (7.6%) | 7.7% | 5.2% | 9.7% | |
| Hospital AML patient volume per year | <.001 | ||||
| ≤50 | 218 (14.9%) | 15.0% | 15.0% | 14.5% | |
| 51-100 | 305 (20.8%) | 19.8% | 23.5% | 20.2% | |
| 101-200 | 649 (44.3%) | 47.3% | 46.2% | 37.2% | |
| >200 | 292 (20.0%) | 17.9% | 15.3% | 28.1% | |
| Geographic location | <.001 | ||||
| West | 189 (12.9%) | 13.9% | 14.5% | 9.7% | |
| Midwest | 385 (26.3%) | 33.1% | 28.1% | 12.2% | |
| South | 627 (42.8%) | 39.0% | 44.5% | 48.2% | |
| Northeast | 263 (18.0%) | 14.0% | 12.8% | 29.9% | |
| Initial clinical presentation | |||||
| Platelet count on admission | <.001 | ||||
| <50 G/L | 788 (53.9%) | 67.9% | 80.6% | 3.6% | |
| 50-150 G/L | 270 (18.4%) | >27.3% | >13.8% | <2.6% | |
| >150 G/L | 30 (2.1%) | 3.3% | <2.8% | <2.6% | |
| Unknown | 376 (25.7%) | <1.5% | <2.8% | >91.2% | |
| Coagulopathy | <.001 | ||||
| Yes | 530 (36.2%) | 40.1% | 64.8% | 2.6% | |
| No | 396 (27.1%) | 42.4% | 23.2% | 3.1% | |
| Unknown | 538 (36.8%) | 17.6% | 12.0% | 94.4% | |
| Time to treatment initiation | .001 | ||||
| Within 2 d of admission | 1376 (94.0%) | >92.0% | >97.2% | 92.4% | |
| ≥3 d after admission | 88 (6.0%) | <8.0% | <2.8% | 7.7% |
| Characteristic . | Overall (N, column %) . | Low risk (column %) . | High risk (column %) . | Unknown risk (column %) . | P . |
|---|---|---|---|---|---|
| Sample N (row %) | 1464 | 706 (48.2%) | 366 (25.0%) | 392 (26.8%) | |
| Age (median, 53 y; IQR, 38-65 y) | .76 | ||||
| ≤39 y | 389 (26.6%) | 26.6% | 24.3% | 28.6% | |
| 40-59 y | 543 (37.1%) | 37.0% | 38.8% | 35.7% | |
| ≥60 y | 532 (36.3%) | 36.4% | 36.9% | 35.7% | |
| Sex | .97 | ||||
| Male | 724 (49.5%) | 49.3% | 49.2% | 50.0% | |
| Female | 740 (50.5%) | 50.7% | 50.8% | 50.0% | |
| Race | .001 | ||||
| White | 1024 (70.0%) | 74.9% | 67.5% | 63.3% | |
| African American | 190 (13.0%) | 11.5% | 13.9% | 14.8% | |
| Other/unknown | 250 (17.1%) | 13.6% | 18.6% | 21.9% | |
| Ethnicity | <.001 | ||||
| Hispanic | 154 (10.5%) | 8.5% | 9.8% | 14.8% | |
| Non-Hispanic | 1124 (76.8%) | 80.7% | 80.1% | 66.6% | |
| Unknown | 186 (12.7%) | 10.8% | 10.1% | 18.6% | |
| Primary payer source | .09 | ||||
| Commercial | 672 (45.9%) | 48.4% | 43.4% | 43.6% | |
| Medicaid | 280 (19.1%) | 17.3% | 22.4% | 19.4% | |
| Medicare | 432 (29.5%) | 30.0% | 26.8% | 31.1% | |
| Other | 80 (5.5%) | 4.3% | 7.4% | 5.9% | |
| AAMC teaching status | .06 | ||||
| Academic medical center | 1353 (92.4%) | 92.4% | 94.8% | 90.3% | |
| Non-academic medical center | 111 (7.6%) | 7.7% | 5.2% | 9.7% | |
| Hospital AML patient volume per year | <.001 | ||||
| ≤50 | 218 (14.9%) | 15.0% | 15.0% | 14.5% | |
| 51-100 | 305 (20.8%) | 19.8% | 23.5% | 20.2% | |
| 101-200 | 649 (44.3%) | 47.3% | 46.2% | 37.2% | |
| >200 | 292 (20.0%) | 17.9% | 15.3% | 28.1% | |
| Geographic location | <.001 | ||||
| West | 189 (12.9%) | 13.9% | 14.5% | 9.7% | |
| Midwest | 385 (26.3%) | 33.1% | 28.1% | 12.2% | |
| South | 627 (42.8%) | 39.0% | 44.5% | 48.2% | |
| Northeast | 263 (18.0%) | 14.0% | 12.8% | 29.9% | |
| Initial clinical presentation | |||||
| Platelet count on admission | <.001 | ||||
| <50 G/L | 788 (53.9%) | 67.9% | 80.6% | 3.6% | |
| 50-150 G/L | 270 (18.4%) | >27.3% | >13.8% | <2.6% | |
| >150 G/L | 30 (2.1%) | 3.3% | <2.8% | <2.6% | |
| Unknown | 376 (25.7%) | <1.5% | <2.8% | >91.2% | |
| Coagulopathy | <.001 | ||||
| Yes | 530 (36.2%) | 40.1% | 64.8% | 2.6% | |
| No | 396 (27.1%) | 42.4% | 23.2% | 3.1% | |
| Unknown | 538 (36.8%) | 17.6% | 12.0% | 94.4% | |
| Time to treatment initiation | .001 | ||||
| Within 2 d of admission | 1376 (94.0%) | >92.0% | >97.2% | 92.4% | |
| ≥3 d after admission | 88 (6.0%) | <8.0% | <2.8% | 7.7% |
Risk status was defined in accordance with NCCN guidelines based on WBC count on admission as low (WBC ≤10 G/L), high (WBC >10 G/L), or unknown (no WBC on admission available) risk. P values refer to the comparison of observed and expected frequency distributions of a given row variable across disease risk as assessed by Pearson’s χ2 test. In line with data-user agreement, cell sizes with <10 patients were suppressed to protect privacy rights. AAMC, American Association of Medical Colleges. Data from the Vizient CDB used with permission of Vizient, Inc. All rights reserved.